Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

Contributed by: PR Newswire

Tags

Keymed-CM313

More Like This

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Keymed Biosciences Announces Interim Results for First Half of 2024

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Keymed Biosciences Announces 2023 Annual Results and Business Updates

PR Newswire associated0

Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis

PR Newswire associated0

ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results